Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Consensus Price Target of $134.68

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received an average rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, twenty-three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $134.68.

Several equities research analysts have commented on the company. TD Cowen upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Bank of America raised their price target on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Citigroup lifted their price objective on shares of Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 5th. Truist Financial boosted their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, BTIG Research reissued a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 25th.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $112.08 on Friday. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of -34.59 and a beta of 1.98. The stock’s 50-day moving average is $115.14 and its 200-day moving average is $100.40. Kymera Therapeutics has a one year low of $55.26 and a one year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%. The company had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same period in the prior year, the firm earned ($0.95) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 465.2% compared to the same quarter last year. On average, equities analysts expect that Kymera Therapeutics will post -3.83 EPS for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. The trade was a 11.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 15.98% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in Kymera Therapeutics by 79.3% during the third quarter. GAMMA Investing LLC now owns 814 shares of the company’s stock worth $91,000 after acquiring an additional 360 shares in the last quarter. Squarepoint Ops LLC boosted its position in Kymera Therapeutics by 657.0% during the second quarter. Squarepoint Ops LLC now owns 97,189 shares of the company’s stock valued at $11,145,000 after purchasing an additional 84,350 shares during the last quarter. Nykredit A S bought a new position in Kymera Therapeutics in the second quarter valued at approximately $207,000. Allianz Asset Management GmbH bought a new position in Kymera Therapeutics in the second quarter valued at approximately $516,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Kymera Therapeutics in the second quarter valued at approximately $344,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.